Migraine Clinical Trial
— STAROfficial title:
STudio Osservazionale Sull'Efficacia, Sicurezza e tollerabilità di Atogepant in Pazienti Real Life Affetti da Emicrania in Italia (Studio STAR)
NCT number | NCT06414044 |
Other study ID # | RICe_4 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | May 9, 2024 |
Est. completion date | April 2026 |
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of atogepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | April 2026 |
Est. primary completion date | September 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III); - At least 3 monthly migraine days; - Good compliance to study procedures; - Availability of headache diary at least of the preceding months before enrollment. Exclusion Criteria: - Subjects with contraindications for use of gepants; - Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments; - medical comorbidities that could interfere with study results; - Pregnancy and breastfeeding. |
Country | Name | City | State |
---|---|---|---|
Italy | SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi | Florence | |
Italy | Fondazione Policlinico Campus Bio-Medico | Roma |
Lead Sponsor | Collaborator |
---|---|
University of Florence | ASST Spedali Civili, Brescia, Auxologico San Luca, Milano, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Azienda Ospedaliera S. Maria della Misericordia, Azienda Ospedaliero Universitaria Policlinico Modena, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Azienda Ospedaliero-Universitaria di Parma, Azienda Policlinico Umberto I, Cliniche Humanitas Gavazzeni, Euganea Health Unit, Padua, Italy, Fondazione Policlinico Universitario Campus Bio-Medico, IRCCS National Neurological Institute "C. Mondino" Foundation, Ospedale di Prato, Società italiana per lo studio delle Cefalee (SISC), Università degli Studi dell'Aquila, University of Campania "Luigi Vanvitelli", University of Roma La Sapienza |
Italy,
Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, Szegedi A. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020 Sep;19(9):727-737. doi: 10.1016/S1474-4422(20)30234-9. Erratum In: Lancet Neurol. 2020 Nov;19(11):e10. — View Citation
Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U, Guo H, Schwefel B, Lu K, Boinpally R, Miceli R, De Abreu Ferreira R, McCusker E, Yu SY, Severt L, Finnegan M, Trugman JM. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Sep 2;402(10404):775-785. doi: 10.1016/S0140-6736(23)01049-8. Epub 2023 Jul 26. Erratum In: Lancet. 2023 Sep 2;402(10404):774. Lancet. 2023 Oct 14;402(10410):1328. — View Citation
Schwedt TJ, Lipton RB, Ailani J, Silberstein SD, Tassorelli C, Guo H, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM. Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial. Cephalalgia. 2022 Jan;42(1):3-11. doi: 10.1177/03331024211042385. Epub 2021 Sep 14. — View Citation
Tassorelli C, Nagy K, Pozo-Rosich P, Lanteri-Minet M, Sacco S, Nezadal T, Guo H, De Abreu Ferreira R, Forero G, Trugman JM. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. Lancet Neurol. 2024 Apr;23(4):382-392. doi: 10.1016/S1474-4422(24)00025-5. Epub 2024 Feb 13. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes in the number of monthly migraine days with aura (quantitative) | Changes in monthly migraine days with aura across treatment (continuous variable, through headache diary assessment) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Other | Variation of duration of aura (qualitative) | Changes in duration of aura across atogepant treatment (continuous variable - minutes, assessed through headache diary) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Other | Variation of type of aura (qualitative) | Changes in type of aura across atogepant treatment (qualitative variable - assessed through headache diary and anamnestic data collection) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Other | MMDs reduction in patients Non-responders to mAbs | Change of monthly migraine days across treatment in those patients who did not respond to anti-CGRP mAbs (continuous variable) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Other | Percentage of 50% Responders across treatment in patients Non-responders to mAbs | Percentage of 50% Responders across treatment in those patients who did not respond to anti-CGRP mAbs (continuous variable) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Other | Menstrually-related migraine | Change in the number of menstrually-related attacks (according to ICHD-3) across treatment compared to baseline (continuous variable) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Other | Change in self-reported effectiveness of treatment | Change in Patients Global Impression of Change (PGIC) questionnaire across treatment (continuous variable, scale 0-7, 1 very much improved, 2 much improved, 3 minimally improved, 4 no change, 5 minimally worse, 6 much worse, 7 very much worse) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Other | Changes in migraine severity | Changes in migraine severity (continuous variable, 0-10 numerical rating scale, higher scores indicate higher severity) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Other | Changes in migraine duration | Changes in migraine duration (continuous variable- hours- assessed through a paper diary) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Other | Changes in duration of the most bothersome symptom(s) | Changes in duration of the most bothersome symptom(s) across treatment (continuous variable, minutes, assessed through a paper diary) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Other | Changes in severity of the most bothersome symptom(s) | Changes in severity of the most bothersome symptom(s) across treatment (continuous variable: 0-10 scale, higher scores indicate higher severity ) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Primary | Changes in migraine frequency after three months of treatment | Changes in monthly migraine days after three months of treatment with atogepant compared to baseline (continuous variable) | Baseline (T0) - 3 months of treatment with atogepant (T3) | |
Primary | 50% Response after three months of treatment | Percentage of 50% Responders (namely patients who presented a reduction of MMDs >/ = 50% compared to baseline) after three months of treatment with atogepant (continuous variable) | Baseline (T0) - 3 months of treatment with atogepant (T3) | |
Secondary | Changes in migraine frequency across twelve months of atogepant treatment | Changes in monthly migraine days after six and twelve months of treatment with atogepant compared to baseline (continuous variable) | Baseline (T0) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Secondary | Percentage of 50% Responders (namely patients who presented a reduction of MMDs >/ = 50% compared to baseline) across twelve months of treatment with atogepant | Percentage of 50% Responders (namely patients who presented a reduction of MMDs >/ = 50% compared to baseline) after six and twelve months of treatment with atogepant (continuous variable) | Baseline (T0) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Secondary | Evaluation of any adverse event (qualitative) | Type of any adverse events in patients receiving atogepant during the observation period (categorical variable) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Secondary | Evaluation of any adverse event (quantitative) | Percentage of reported adverse events in patients receiving atogepant assessed quarterly during the observation period (continuous variable) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Secondary | Evaluation of serious adverse event | Percentage of serious adverse events (namely those resulting in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect) in patients receiving atogepant during the observation period (continuous variable) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Secondary | Evaluation of adverse event leading to treatment discontinuation | Percentage of adverse events leading to treatment discontinuation in patients receiving atogepant during the observation period (continuous variable) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Secondary | Consistency of treatment response | Percentage of patients with a stable 50% response across twelve months of atogepant treatment (continuous variable) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Secondary | Changes in migraine disability (MIDAS) | Changes in MIgraine Disability ASsement questionnaire across treatment (continuous variable, 0-270 scale, higher scores indicate higher disability: 0-5, little/no disability; 6-10, mild disability; 11-20, moderate disability; >20, severe disability) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Secondary | Changes in migraine disability (HIT-6) | Changes in Headache Impact Test-6 questionnaire across treatment (continuous variable, 36-78 scale, higher scores indicates greater disability) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Secondary | Changes in response to acute migraine treatment (m-TOQ) | Changes in migraine Treatment Optimization Questionnaire across treatment (continuous variable, 0-8 scale, higher score indicates higher acute therapy effectiveness) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Secondary | Changes in allodynia (ASC-12) | Changes in Allodynia Symptoms Checklist-12 questionnaire across treatment (continuous variable, 0-24 scale, higher score indicates more severe allodynia) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Secondary | Changes in quality of life across atogepant treatment (MSQ) | Changes in Migraine Specific Quality of life questionnaire across treatment (continuous variable, 0-100 scale, 100 indicates full functionality) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Secondary | Changes in interictal burden across atogepant treatment (MIBS-4) | Changes in Migraine Interictal Burden Scale-4 questionnaire across treatment (continuous variable, 0-4 scale, 0 indicates no interictal burden, 1-2 mild level of interictal burden, 3 moderate interictal burden, 4 severe interictal burden) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Secondary | Self-reported treatment effectiveness | Changes in Migraine Assessment of Current Therapy (Migraine-ACT) a 4-item questionnaire about treatment effectiveness and daily life repercussions, across treatment compared to baseline (continuous variable, 0-4 scale, higher scores indicates higher acute treatment effectiveness) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant | |
Secondary | Percentage of patients with Medication overuse headache reverted during treatment | Percentage of patients with a baseline diagnosis of MOH reverted after 3 - 6 and 12 months of treatment (continuous variable) | Baseline (T0) - 3 months (T3) - 6 months (T6) - 12 months (T12) of treatment with atogepant |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05525611 -
Cabergoline as a Preventive Treatment for Chronic Migraine
|
N/A | |
Completed |
NCT06192173 -
Patent Foramen Ovale Closure in Migraine
|
||
Recruiting |
NCT03832998 -
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
|
Phase 3 | |
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
Completed |
NCT06304675 -
Manageable Environmental Factors in Migraine
|
||
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
Completed |
NCT04179474 -
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
|
Phase 1 | |
Recruiting |
NCT04603976 -
Registry for Migraine - Clinical Core
|
Phase 4 | |
Completed |
NCT03597529 -
CHOCOlate MeLatonin for AdolescenT MigrainE
|
Phase 2 | |
Completed |
NCT04197349 -
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
|
Phase 1 | |
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Active, not recruiting |
NCT05064371 -
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
|
Phase 3 | |
Suspended |
NCT04069572 -
Vibratory Stimulation for the Treatment of Chronic Pain
|
N/A | |
Not yet recruiting |
NCT04859374 -
Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach
|
N/A | |
Not yet recruiting |
NCT03083860 -
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.
|
N/A | |
Completed |
NCT02905227 -
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
|
Phase 1 | |
Enrolling by invitation |
NCT02532023 -
The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients
|
Phase 4 | |
Completed |
NCT02108678 -
One-Day Intervention for Depression and Impairment in Migraine Patients
|
N/A |